The Short-Form Health Survey (SF-36) is a robust measure of general health, with a score of ~50 representing the normative population. Eptinezumab, a selective and potent anti-CGRP monoclonal antibody, demonstrated significant reductions in monthly migraine days (primary efficacy endpoint) in patients with EM (NCT02559895) or CM (NCT02974153).

Adults with EM (N=888) or CM (N=1072) were randomized to eptinezumab 100mg, 300mg, or placebo (or 30mg in EM trial). QoL was evaluated descriptively using the SF-36 v2.0, administered at baseline, Week (Wk) 4, and Wk12. Patients in this analysis were stratified by baseline SF-36 scores (<35, 35-39, 40-44, 45-49, ≥50).

In patients with baseline SF-36 of <35, mean Mental Component Summary (MCS) score increased by 13.9 (300mg), 12.4 (100mg), and 7.2 (placebo), and mean Physical Component Summary (PCS) score increased by 11.0, 8.2, and 4.6 points, respectively, from baseline. In patients with baseline SF-36 of 35-39, mean MCS increased by 6.7 (300mg), 5.6 (100mg), and 4.5 (placebo), and mean PCS score increased by 7.8, 6.9, and 6.5 points, respectively, from baseline. In patients with baseline SF-36 of 40-44, mean MCS increased by 5.0 (300mg), 4.2 (100mg), and 4.3 (placebo), and mean PCS increased by 5.3, 4.7, and 3.2 points, respectively, from baseline. As expected, minimal improvement was observed in patients with normative population scores at baseline. Improvements were maintained or further improved for eptinezumab-treated patients through Wk12.

In migraine patients with diminished QoL, eptinezumab demonstrated rapid clinically meaningful improvements in SF-36 scores within the first month after the first infusion, with changes maintained or further improved through 3 months. Patients with worse QoL at baseline experienced greater improvements throughout the infusion period.